DE-INCYTE
21.8.2024 17:41:34 CEST | Business Wire | Press release
Incyte (Nasdaq: INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.
"The data at ESMO underscore the progress across our oncology portfolio and the potential to impact patients where additional treatment options are needed. Notably, a Presidential Symposium will feature new, pivotal results from the Phase 3 POD1UM-303/InterAACT2 study of retifanlimab (Zynyz®) for the treatment of squamous cell anal carcinoma (SCAC). The POD1UM-303 data will support the supplemental Biologics License Application (sBLA) filing for retifanlimab in SCAC planned by year end 2024," said Pablo Cagnoni M.D., President, Head of Research and Development, Incyte. "We will also present new data on INCB123667, a potential first-in-class CDK2 inhibitor, which we believe has the potential to enhance outcomes and serve as a foundational treatment for platinum-resistant ovarian and other cancers."
Details on the abstracts accepted for presentation at ESMO include:
Presidential Symposium
Retifanlimab (PD-1)
POD1UM-303/InterAACT2: Phase 3 Study of Retifanlimab With Carboplatin-Paclitaxel (C-P) in Patients (Pts) With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy
Presidential Symposium I: Practice-changing trials. Presentation Number: LBA2. Presentation Time: 10:50-11:02 a.m. ET (4:50-5:02 p.m. CET), September 14, 2024
Mini Oral Session
INCB123667
Safety and Tolerability of INCB123667, a Selective CDK2 Inhibitor, in Patients (Pts) With Advanced Solid Tumors: A Phase 1 Study
Mini oral session: Developmental therapeutics. Presentation Number: 617MO. Presentation Time: 9:35 – 9:40 a.m. ET (3:35-3:40 p.m. CET), September 14, 2024
Conference Call and Webcast
Incyte will host an in-person analyst and investor event on Saturday, September 14, 2024, from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST) to discuss key data presentations at ESMO including data from the POD1UM-303 Presidential Symposia and its CDK2 inhibitor program. The CDK2 data presentation will include new results from a later data cut-off, as well as the data included in the ESMO accepted abstract and mini-oral presentation. The event will be webcasted and can be accessed via the Events and Presentations tab of the Investor section of Incyte.com and it will be available for replay for 90 days.
Conference call details will be provided on the Investor section of Incyte.com.
Abstracts will be available to registered attendees on the ESMO Virtual Congress platform beginning on September 9, 2024. All accepted abstracts will be published in the ESMO Congress 2024 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
More information regarding the 2024 ESMO Congress can be found at https://www.esmo.org/meeting-calendar/esmo-congress-2024.
About Retifanlimab (Zynyz®)
Retifanlimab (Zynyz®), is an intravenous PD-1 inhibitor indicated in the U.S. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Zynyz is marketed by Incyte in the U.S. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.
Zynyz is a trademark of Incyte.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, the potential for retifanlimab and INCB123667 to positively impact patients and plans to submit an sBLA for retifanlimab in SCAC by year end 2024, contain predictions, estimates, and other forward-looking statements.
These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of the United States; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended June 30, 2024. We disclaim any intent or obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821420609/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arc'teryx Introduces System 0™, a New Framework for the Future of Product Design and Circularity26.8.2026 15:00:00 CEST | Press release
Sperro SV, a multisport mountain-grade hardshell built with circular design principles, available September 4, 2026 Arc'teryx Equipment, the global design company specializing in technical high-performance apparel and equipment, today introduced System 0™, a new framework that reimagines how products can be designed, manufactured, used, repaired, and ultimately regenerated. System 0 represents the next evolution for sustainability in the outdoor industry, as it embeds circular thinking across an entire product lifecycle while maintaining the uncompromising performance standards that define the Arc’teryx brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826686539/en/ Arc’teryx athlete, Craig Murray, wearing the Sperro SV, a multisport mountain-grade hardshell built with circular design principles, available September 4, 2026. The first product being introduced as part of the System 0 platform is the Sperro SV jacket, a
Xsolla Announces Five-Year Partnership With the Global Esports Federation26.8.2026 15:00:00 CEST | Press release
Partnership Represents a Structural Shift in Esports, Placing Xsolla's Infrastructure Behind GEF’s Entire Ecosystem, Spanning Commerce, Payments, Wallet, Loyalty, and Distribution Across Global Esports Games, Global Esports Tour, and 180+ Member Federations Xsolla, a global commerce company, today announced a landmark five-year strategic partnership with the Global Esports Federation (GEF), the world-convening body for esports. As GEF's exclusive partner for commerce, payments, wallet, loyalty, and distribution, Xsolla will power the entire GEF ecosystem, including the flagship Global Esports Games, pro-series Global Esports Tour, global GEFcon, and 180+ Member Federations across five continents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826948844/en/ Graphic: Xsolla The announcement comes as GEF marks 100 days to go to the Los Angeles 2026 Global Esports Games (GEGLA26), adding further momentum to the road to Los An
NABEP Appoints Sara Chouraqui as General Counsel26.8.2026 15:00:00 CEST | Press release
Company expands legal team as it prepares for significant growth North American Blue Energy Partners (NABEP) has appointed Sara Chouraqui as General Counsel, with Elizabeth Collery and Victoria Jacobson each joining as Deputy General Counsel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826168543/en/ Sara Chouraqui joins NABEP as its General Counsel, bringing decades of legal expertise. These additions significantly strengthen NABEP’s senior leadership team and legal expertise as the company improves its operations, increases production and develops new strategic and commercial partnerships. As General Counsel, Chouraqui will lead NABEP’s global legal function and advise the company’s leadership on its legal, regulatory and corporate priorities, including major transactions and partnerships, governance, compliance and the management of legal and regulatory risk across the company’s operations. Her experience navigating
Grafana Labs Crosses 10,000-Customer Milestone as AI Adoption Accelerates Growth Across the Platform26.8.2026 15:00:00 CEST | Press release
Grafana Labs was recently recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Observability Platforms for the third consecutive year, launched six AI-native products during its inaugural AI Week, and surpassed $600M in Annual Recurring Revenue. Grafana Labs, the company behind the open observability cloud, today announced it has crossed 10,000 customers worldwide and surpassed $600 million in annual recurring revenue, as organizations standardize on open observability for the AI era. Teams need AI to help them understand their own systems faster, especially as complexity and overhead remain the top observability concern cited in Grafana Labs' 2026 Observability Survey – a need reflected by the adoption of Grafana Assistant, Grafana Cloud's context-aware AI agent for exploring and troubleshooting observability data, now used by more than 18,000 organizations. Teams also need observability purpose-built for AI systems themselves: When teams move AI into production, models dri
FlightSafety International Reaches Agreement to Acquire Acron Technologies’ Commercial Training Solutions26.8.2026 15:00:00 CEST | Press release
Agreement will expand FlightSafety’s training and simulation capabilities in the global commercial aviation market FlightSafety International Inc. (FSI), a leading global provider of aviation training and simulation technology, today announced it has signed a definitive agreement with Acron Technologies, a portfolio company of TJC LP, to acquire its Commercial Training Solutions (CTS) business, including its Training Systems, Training Services, Aviation Academy, and Driver Training portfolio. The agreement marks a significant expansion of FSI’s capabilities in the commercial aviation market, broadening and complementing its simulator manufacturing capabilities and global training footprint. CTS brings over eight decades of experience in commercial aviation training and simulation. With a long-standing heritage in commercial airline simulator manufacturing, CTS has delivered more than 850 training devices throughout its history, with over 300 full-flight simulators currently in operatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom